



NSW
Therapeutic
Advisory
Group Inc.

Advancing
quality use
of medicines
in NSW

Fortnightly TAG Mail – resources list 10th October 2024

NSW TAG ACTIVITIES

2024 Meetings

NSW TAG General Meetings

- 31st October 2.30-4pm

NSW TAG Annual General Meeting

- 31st October 4- 4.30pm

Open email discussions- nil

Recently completed email discussions and surveys

- Local written procedures outlining documentation requirements for handling of ADRs incl reporting to DTCs

- Protocols for critical medicines in NSW public facilities

- Ongoing infliximab for immune therapy colitis

- Handling of medicines by perfusionists

Contact *Sasha Bennett* at sasha.bennett@svha.org.au for further information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

AJHP: Evaluating the impact of an automated drug retrieval cabinet and robotic dispensing system in a large hospital central pharmacy - [link](#)

AJHP: Collaborative pharmacy research across integrated health systems- [link](#)

AIM: NIH COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned - [link](#)

BJCP: Evaluating the capability of ChatGPT in predicting drug–drug interactions- [link](#)

BMJ: Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer's drug - [link](#)

BMJ: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline - [link](#)

BMJ: Regulator's list of 50 substandard drugs raises questions about oversight and manufacturing in India - [link](#)

BMJ: Switching from inhaled to intravenous general anaesthesia - [link](#)

CJEM: - Intranasal midazolam for procedural distress in children in the emergency department: a systematic review and meta-analysis - [link](#)

ContempNurs: Reduction in preventable time-critical dose omissions: impact of electronic medication management systems on in-patients - [link](#)

IMJ: Position Paper: Navigating high-cost medicines: summary of the Guiding Principles for the governance of high-cost medicines in Australian hospitals - [link](#)

IJCP: - Implementation and evaluation of specialist heart failure pharmacist prescribing clinics - [link](#)

IJCP: Association of polypharmacy with clinical outcomes and healthcare utilization in older adults with cardiometabolic diseases: a retrospective cohort study - [link](#)

JAGS: Association between potentially inappropriate medications prescription and health-related quality of life among US older adults - [link](#)

JAMA: N-of-1 Studies in an Era of Precision Medicine - [link](#)

JAMA: Making Pragmatic Clinical Trials More Pragmatic - [link](#)

JAMA Card: Estimated Long-Term Benefits of Finerenone in Heart Failure - [link](#)

JAMA Card: Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure - [link](#)

JAMA IntMed: Masked Taper With Behavioral Intervention for Discontinuation of Benzodiazepine Receptor Agonists: A Randomized Clinical Trial - [link](#)

JAMA NO: Semaglutide and Opioid Overdose Risk in Patients with Type 2 Diabetes and Opioid Use Disorder - [link](#)

JAMA Ped: Cannabinoids Used for Medical Purposes in Children and Adolescents: A Systematic Review and Meta-Analysis - [link](#)

JPS: Implementation and Evaluation of Clinical Decision Support for Apixaban Dosing in a Community Teaching Hospital - [link](#)

JPPR: Active Ingredient Prescribing in Australia: exploring pharmacists' experiences - [link](#)
Lancet HIV: - HIV incidence in people receiving government-subsidised pre-exposure prophylaxis in Australia: a whole-of-population retrospective cohort study - [link](#)
Lancet Onc: Rising costs of cancer medicines - [link](#) ; The tyranny of non-inferiority trials - [link](#)
MDPI: Clinical Outcomes of Benzodiazepine Prescribing for People Receiving Opioid Agonist Treatment- [link](#)
MJA: Adherence to clinical care standards and mortality after hip fracture surgery in New South Wales, 2015–2018- [link](#)
MJA: Aligning legislation with clinical practice: off-label prescribing under the microscope - [link](#)
Neurology: Duration of Benefit and Risk of Dual Antiplatelet Therapy up to 72 Hours After Mild Ischemic Stroke and Transient Ischemic Attack - [link](#)
PedQualSaf: Reducing falls in hospitalized children and adolescents with cancer and blood disorders: a quality improvement journey - [link](#)
Prescrire Int: - Drugs to avoid in the name of better patient care - [2024 update](#)
Ped: - Opioid Prescribing for Acute Pain Management in Children and Adolescents in Outpatient Settings: Clinical Practice Guideline - [link](#)
Thorax: - GLP-1 Ras may benefit cardiopulmonary outcomes in patients with COPD - [link](#)

OTHER NEWS

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- First national COPD Clinical Care Standard – coming soon - [link](#)

NSW Health

- Vaccination the best protection against mpox [[3 October 2024](#)]
- Warning: High-dose MDMA tablets (ecstasy) circulating in NSW [[2 October 2024](#)]
- Serious scarcity medicine substitution; Approval for use of an Electronic National Residential Medication Chart (eNRMC) - [link](#)

TGA

- Updates to the Prescribing Medicines in Pregnancy database - September 2024 - [link](#)
- Enhanced product standards for therapeutic vapes in 2025 - [link](#)
- Therapeutic vapes available without a prescription following consultation with a pharmacist - [link](#)

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)

The latest weekly Evidence Digest can be found [here](#)

Australian Living Evidence Collaboration (ALEC)

- Australian Pregnancy Care Guideline - includes updated and new recommendations for hypertension and pre-eclampsia - [link](#)
-- Strong recommendation: Use aspirin 150mg/day for those at high risk of developing preeclampsia, unless contraindicated, commencing before 16 weeks' gestation where possible
-- Conditional recommendation against: Do not universally recommend aspirin to those at low risk of preeclampsia; Do not routinely use low molecular weight heparin (LMWH) in addition to aspirin for prevention of preeclampsia
- Australian Postnatal Care Guideline - [link](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Joint Statement: Working together to achieve sustainable high-quality health care in a changing climate - [link](#)
- Medication without harm – WHO Global Patient Safety Challenge: Australia's Response – [status report](#) – [priority action status summary](#)
- Real-Time Prescription Monitoring resources - [link](#)

Australian Government Department of Health

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988
Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au
An initiative of NSW clinical pharmacologists & pharmacists
ABN: 82 707 308 091

- New Aged Care Infection Prevention and Control Guide – [Video](#) - [Webinar](#)
- Obesity epidemic in Australia – [Final report](#)
- Medication Management Review Programs [Dataset](#)

CATAG

- Consumer counselling tool: Understanding high-cost medicines in public hospitals - [link](#)

MIMS monthly updates

- New Products
- Selpercatinib ([Retevmo](#)) - provisional approval for adults with locally advanced or metastatic RET fusion positive non-small cell lung cancer. 40 mg or 80 mg capsules
- Zilucoplan (tetrasodium) ([Zilbrysq](#)) - add-on to standard therapy for generalised myasthenia gravis in adults, who are AChR antibody positive. Contraindicated in patients with unresolved Neisseria meningitidis infection and in patients who are not currently vaccinated against Neisseria meningitidis, unless they receive appropriate prophylactic antibiotic treatment until 2 weeks after the first vaccination dose. Various strengths in prefilled syringes.
- New Presentation
- Tirzepatide ([Mounjaro](#)) - multidose prefilled pen 4 doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg or 15 mg in 0.6 mL
- New Indication
- Tirzepatide ([Mounjaro](#)) - adjunct to a reduced-calorie diet and increased physical activity for chronic weight management, including weight loss and weight maintenance, in adults with an initial body mass index of ≥ 30 kg/m² (obesity) or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes mellitus)

Safer Care Victoria

- Victorian Safety Culture Guide - [link](#)
- Morbidity and Mortality meetings – Framework and toolkit - [link](#)

TGA

- [Database](#) of section 19A approvals to import and supply medicines to address medicine shortages
- AusPARs:
 - [Nubega](#) has been approved to treat metastatic hormone-sensitive prostate cancer in combination with docetaxel
- Australian prescription medicine decision summaries:
 - Voranigo (vorasidenib) for Grade 2 astrocytoma or oligodendroglioma in adults and paediatric patients 12 years and older who are not in need of immediate chemotherapy or radiotherapy following surgical intervention

REPORTS AND PUBLICATIONS – INTERNATIONAL

Agency for Healthcare Research and Quality (AHRQ) USA

- Zero Harm: Striving to Reduce Preventable Harms – Point, Counterpoint, and Areas of Agreement - [link](#)

British Generic Manufacturers Association

- Solutions to UK Medicines Shortages - [link](#)

Canadian Agency for Drugs and Technologies in Health

- Lenvatinib for the Treatment of Hepatocellular Carcinoma After Liver Transplant - [link](#)
- Switching Calcitonin Gene-Related Peptide Inhibitors for Migraine Prophylaxis - [link](#)
- Association Between Opioid Use and the Development of Diverticulitis - [link](#)

electronic Medicines Compendium (eMC) (UK)

- [New products](#)

- Iqirvo (elafibrator) tablets - for primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy unable to tolerate UDCA
- Sogroya (somapacitan) in pre-filled pen - long-acting recombinant human growth hormone derivative licensed for replacement of endogenous growth hormone in children aged ≥ 3 years, and adolescents with growth failure due to growth hormone deficiency, and in adults with growth hormone deficiency

European Medicines Agency (EMA)

- EMA recommends suspension of sickle cell disease medicine Oxbryta - [link](#)

Food and Drug Administration (FDA) USA

- Alerts to patients and healthcare professionals about the voluntary withdrawal of Oxbryta from the market due to safety concerns - [link](#)
- New Drug approvals
 - neoadjuvant/adjuvant [nivolumab](#) for resectable non-small cell lung cancer
 - imaging drug for evaluation of myocardial ischemia and infarction - [Flyrcado](#) (flurpiridaz F 18)
 - [selpercatinib](#) for medullary thyroid cancer with a RET mutation
 - First Home Flu and COVID-19 Combination Test Outside of Emergency Use Authorities - [link](#)
 - [Dupilumab](#) as Add-On for COPD

Healthcare Quality Improvement Partnership, UK

- Cardiovascular Disease-Inequalities in cholesterol management by sex (CVDPrevent) - [link](#)

Medicines and Healthcare products Regulatory Agency (MHRA)

- Elafibrator approved as first medicine to treat adults primary biliary cholangitis - [link](#)
- Approves first medicine for activated phosphoinositide 3-kinase delta syndrome (APDS) - [link](#)
- Report safety concerns with insulin pumps and continuous glucose monitoring equipment - [link](#)

NHS England

- Urgent and emergency mental health care for children and young people: national implementation guidance - [link](#)

NHS Scotland

- Accepted for use:
 - [Faricimab](#) (Vabysmo®) for visual impairment due to macular oedema secondary to retinal vein occlusion
 - [Pembrolizumab](#) (Keytruda®) for non-small cell lung cancer (NSCLC) at high risk of recurrence
 - [Relugolix](#) (Orgovyx®) for prostate cancer
 - [Selinexor](#) (Nexpovio®) for refractory multiple myeloma
- Accepted for restricted use:
 - [Rezafungin](#) acetate (Rezzayo®) for invasive candidiasis
 - [Selinexor](#) (Nexpovio®) for multiple myeloma in adults who have received at least one prior therapy

National Institute for Health and Care Excellence (NICE) UK

- Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension ([TA1009](#))

National Institute for Health and Care Research (NIHR)

- NIHR commentaries: How to make remote consultations safer - [link](#)
- Diagnostic accuracy of point-of-care tests for acute respiratory infection: a systematic review of reviews - [link](#)
- Antidepressants for pain management in adults with chronic pain: a network meta-analysis - [link](#)
- Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling - [link](#)

- Alitretinoin versus phototherapy as the first-line treatment in adults with severe chronic hand eczema: the ALPHA RCT - [link](#)
- NIHR commentaries: Schoolchildren with asthma face different risks at different ages - [link](#)

Neonatal & Paediatric Pharmacists Group

- Safe Use of Transdermal Clonidine Patches in the Management of Childhood Motor and Movement Disorders - [link](#)

Office for Health Improvement and Disparities UK

- Deaths linked to potent synthetic opioids - [link](#)

Patient Safety Learning

- Electronic patient record systems: Putting patient safety at the heart of implementation - [link](#)

Royal Pharmaceutical Society

- ... responds to consultation on puberty blockers - [link](#)
- New RPS and RCGP Repeat Prescribing Toolkit aims to improve patient safety and efficiency - [link](#)

The King's Fund (UK)

- Tackling health inequalities: seven priorities for the NHS – [link](#)
- Public health and population health: leading together - [link](#)

UK Health Security Agency

- Tuberculosis (TB) notifications reported to enhanced TB surveillance systems: UK, 2000-2023 - [link](#)
- Rise in HIV diagnoses steepest among heterosexual men and women - [link](#)
- COVID-19 vaccination: information for healthcare practitioners - [link](#)
- Interventions to reduce harms for people who inject drugs in prisons - [link](#)

World Health Organisation (WHO)

- Accelerating digital health transformation - [link](#)
- WHO adds an HPV vaccine for single-dose use - [link](#)
- Statement of the WHO Global Advisory Committee on Vaccine Safety on the safety of the mpox vaccines for use in high-risk groups - [link](#)
- WHO approves first mpox diagnostic test for emergency use, boosting global access - [link](#)

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)

- [Revised SPCs](#)

- Alkindi (hydrocortisone) - patients and/or caregivers advised to contact their healthcare provider if most of the granules in a dose are regurgitated, vomited or spat out, as a repeat dose may be required to avoid adrenal insufficiency
- Aspaveli (pegcetacoplan) – urticaria added as an undesirable effect (frequency uncommon) based on postmarketing data
- Benilexa (Levonorgestrel) One Handed IUD System effective for eight years for contraception and has demonstrated efficacy for three years for use in heavy menstrual bleeding. It should be removed or exchanged after 8 years of use, or earlier if heavy or bothersome menstrual bleeding returns
- Boostrix-IPV (diphtheria, tetanus, pertussis-acellular and poliomyelitis, inactivated) - immunogenicity & safety data of dTpa vaccination in patients with obstructive airway disease added from descriptive meta-analysis (n=222 adults) showing immune responses consistent with responses obtained in general adult population, and with a similar safety profile
- Brabio (glatiramer acetate) - data on pregnant women (300-1000 pregnancy outcomes) indicate no malformative or feto/neonatal toxicity, and thus Brabio may be considered during pregnancy if necessary. Additionally, SPC now notes Brabio can be used during breast-feeding
- Depo-Medrone (methylprednisolone) with Lidocaine - no additional benefit derives from intramuscular administration of Depo-Medrone with Lidocaine; its administration this way is not

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

recommended. Where parenteral corticosteroid therapy for sustained systemic effect is desired, plain Depo-Medrone should be used

- Evrenzo (roxadustat) – cases of cerebrovascular accidents, including fatal cases of cerebral infarction, reported. An increase in blood copper added as an ADR of unknown frequency
- Fencino (fentanyl) Transdermal Patch – dysphagia added as an uncommon potential ADR
- Imfinzi (durvalumab) - rhabdomyolysis in the list of immune-related ADRs observed in patients treated with durvalumab in combination with tremelimumab, including advice on when to withhold the dose and when it should be permanently discontinued
- Lamictal (lamotrigine) – erythema multiforme added as a rare potential ADR
- Movicol - shelf life of reconstituted solution changed from 24 hours to 6 hours
- Myfortic (mycophenolate sodium) - hypersensitivity reactions (including anaphylaxis) as an ADR reported during post-marketing experience
- Naprosyn (naproxen) Tablets- drug reaction with eosinophilia and systemic symptoms (DRESS) added as rare ADR associated with NSAID use, with highest risk early in the course of therapy. If patients develop DRESS, or any other serious skin reaction, naproxen must be permanently discontinued
- Novofem (estradiol hemihydrate, norethisterone acetate) - drug interaction between lamotrigine and HRT products. Hormone contraceptives containing oestrogens shown to significantly decrease plasma concentrations of lamotrigine, & it is expected that a similar interaction exists with HRT
- Oncaspar (pegaspargase) - hepatic veno-occlusive disease, including severe, life-threatening and potentially fatal cases observed in patients treated with in combination with standard chemotherapy, including during the induction phase of multiphase chemotherapy
- Ozempic, Rybelsus (semaglutide), Victoza (liraglutide), Xultophy (insulin degludec and liraglutide) - warning pulmonary aspiration reported in patients undergoing general anaesthesia (GA)/deep sedation (DS). Increased risk of residual gastric content due to delayed gastric emptying should thus be considered prior to performing procedures with GA/DS
- Rifinah (isoniazid) - alopecia added as an ADR of unknown frequency
- Siklos (hydroxycarbamide) - may interfere with certain continuous glucose monitoring sensors resulting in falsely high readings (compared to actual blood glucose readings)
- Skyrizi (risankizumab) - eczema added as a common potential ADR
- Sodiofolin (folinic acid) - removal of pregnancy as a contraindication for 5-FU treatment
- Suliqua (insulin glargine, lixisenatide) - dysgeusia (taste disorder) added as an ADR of uncommon frequency
- Risk minimisation materials
- Immedica: [pegzilarginase](#) (Loargys) - This guide informs patients/caregivers about the importance of proper handling, preparation & administration to reduce the risk of medication errors, & the risk of hypersensitivity reactions. It should supplement information from the treating doctor & patient information leaflet
- Santhera: [Agamree](#) (vamorolone) 40 mg/ml oral suspension – patient alert card - dissociative corticosteroid for chronic treatment of Duchenne Muscular dystrophy. The card notes it must be taken as prescribed, and that missed doses, illness or surgery can cause adrenal crisis, which requires urgent medical attention
- UCB Pharma: [zilucoplan](#) sodium (Zilbrysq) – HP guide describes potential increased risk of meningococcal infections & requirement for meningococcal vaccines (& prophylactic antibiotics if needed), important information before starting a patient on treatment, and counselling

EMA

- Review of medicines containing finasteride and dutasteride started - assesses data related to suicidal thoughts and behaviours; New safety information for healthcare professionals: risk of medication errors due to change of dosing syringe for Keppra and Levetiracetam UCB oral solution - [link](#)

Medicines and Healthcare products Regulatory Agency (MHRA) UK

- Drug Safety Update [September 2024](#)

Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

- Nitrous Oxide Advisory – [September 2024](#)
- Updates to the Guidelines on the Regulation of Therapeutic Products in New Zealand: Requirements for information for prescribers and consumers - [link](#)

MIMS monthly updates

- New Contraindications
- Dorzolamide (hydrochloride) and timolol (maleate) ([Cosopt](#)) is now contraindicated in patients with sick sinus syndrome, severe renal impairment (CrCl < 30 mL/min) and hyperchloraemic acidosis
- Gemcitabine (hydrochloride) ([DBL Gemcitabine Solution for Injection](#)) is now contraindicated in pregnancy and breastfeeding
- Glecaprevir and pibrentasvir ([Maviret](#)) is now contraindicated for concomitant use with products containing more than 20 mcg of ethinylestradiol
- Trandolapril ([Gopten](#)) is now contraindicated in liver cirrhosis with ascites

Specialist Pharmacy Services NHS UK

- Medication Safety Update [September 2024](#)
- Managing medicines for people with sulfonamide allergy - [link](#)
- Safe management of therapeutic drug monitoring - [link](#)
- Managing the risk of confusion between intravenous penicillin salts - [link](#)

TGA

- Substitution allowed to address shortage of Ryzodeg 70/30 FlexTouch insulin - [September 2024](#)
- Product Information safety updates - [September 2024](#)
- Counterfeit Ozempic pens detected and adverse event reported - [link](#)

PAPERS OF INTEREST

American Journal of Cardiology

- Direct Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Left Ventricular Thrombus After Myocardial Infarction: A Meta-Analysis - [link](#)

American Journal of Clinical Nutrition

- Pregnancy vitamin D supplementation and offspring bone mineral density in childhood - Follow-up of a randomised controlled trial - [link](#)

American Journal of Health-System Pharmacy (AJHP)

- Evaluating the impact of an automated drug retrieval cabinet and robotic dispensing system in a large hospital central pharmacy - [link](#)
- Process evaluation and early outcomes of real-world implementation of a pharmacist-driven cabotegravir/rilpivirine long-acting injectable initiative - [link](#)
- Insomnia in ambulatory care: A clinical review - [link](#)
- Management of obesity - [link](#)
- Collaborative pharmacy research across integrated health systems: A purpose and promise for opportunities to study the complete medication-use process - [link](#)
- The 12-digit National Drug Code – [link](#) ; The National Drug Code explained - [link](#)

Annals of Internal Medicine

- National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned - [link](#)
- The Misplaced Push to Restrict Access to Gabapentin - [link](#)
- Time-Restricted Eating in Adults with Metabolic Syndrome: A Randomized Controlled Trial - [link](#)
- Diabetes Risk Factors in People with HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention: A Randomized Trial - [link](#)
- HIV Reservoir Landscape in Breast Milk from Long-Term Virally Suppressed Individuals - [link](#)

British Journal of Clinical Pharmacology

- Evaluating the capability of ChatGPT in predicting drug–drug interactions: Real-world evidence using hospitalized patient data - [link](#)
- Letter: Cyproheptadine is preferable to benzodiazepines in mild cases of serotonin syndrome (toxicity) - [link](#) - [response](#)
- A systematic review of economic evaluations of orphan medicines for the management of spinal muscular atrophy - [link](#)
- Psychedelic research, assisted therapy and the role of the anaesthetist: A review and insights for experimental and clinical practices - [link](#)

British Journal of General Practice

- Managing chronic cough in adults in primary care - [link](#)
- What's new in osteoporosis management? Leading the fight in primary care - [link](#)
- Healthcare avoidance during the early stages of the COVID-19 pandemic and all-cause mortality: a longitudinal community-based study - [link](#)

British Journal of Psychiatry

- Mortality associated with clozapine: what is the evidence? - [link](#)
- Clozapine monitoring requirements: is it time for an update? - [link](#)
- Maternal mental disorders and neonatal outcomes: Danish population-based cohort study - [link](#)

British Medical Journal (BMJ)

- Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer's drug - [link](#)
- World leaders commit to reduce deaths from antimicrobial resistance (AMR) by 10% by 2030 - [link](#)
- Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline - [link](#)
- Regulator's list of 50 substandard drugs raises questions about oversight and manufacturing in India - [link](#)
- Switching from inhaled to intravenous general anaesthesia - [link](#)
- How covid, flu, and other seasonal vaccine programmes are changing - [link](#)
- Protecting healthcare and patient pathways from infection and antimicrobial resistance - [link](#)
- Research priorities for future shocks - [link](#)

BMJ Open

- Association of early statin initiation during COVID-19 admission with inpatient mortality at an academic health system in Illinois, March 2020 to September 2022: a target trial emulation using observational data - [link](#)
- Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study - [link](#)

Canadian Journal of Emergency Medicine

- Intranasal midazolam for procedural distress in children in the emergency department: a systematic review and meta-analysis - [link](#)

Circulation

- Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial - [link](#)
- Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure - [link](#)
- Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a Prespecified Analysis of The FINEARTS-HF Trial - [link](#)
- Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Elevation Myocardial Infarction: STREAM-2 1-Year Mortality Follow-Up - [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

Cochrane

- Vitamin D for the management of chronic obstructive pulmonary disease - [link](#)

Contemp Nurse

- Reduction in preventable time-critical dose omissions: impact of electronic medication management systems on in-patients - [link](#)

CNS Drugs

- Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study - [link](#)

Diabetes Care

- Continuous Glucose Monitoring With Geriatric Principles in Older Adults With Type 1 Diabetes and Hypoglycemia: A Randomized Controlled Trial - [link](#)

- Advanced Hybrid Closed-Loop Therapy Compared With Standard Insulin Therapy Intrapartum and Early Postpartum in Women With Type 1 Diabetes: A Secondary Observational Analysis From the CRISTAL Randomized Controlled Trial - [link](#)

- Metformin Use and Risk of Delirium in Older Adults With Type 2 Diabetes - [link](#)

Diabetes, Obesity and Metabolism

- A meta-analysis of randomized controlled studies examining the effects of sodium-glucose co-transporter-2 inhibitors on peripheral artery disease and risk of amputations - [link](#)

European Heart Journal

- Breast cancer and cardiovascular health - [link](#)

- Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study - [link](#)

- Non-vitamin K oral anticoagulants in valvular heart disease before surgery: a tale of bridging vs. no bridging - [link](#)

European Journal of Hospital Pharmacy

- Ceftriaxone-induced thrombocytopenia during tuberculosis treatment: a case report - [link](#)

- A single harmonised pharmacy process to improve clinical trial set-up times - [link](#)

Internal Medicine Journal

- Position Paper: Navigating high-cost medicines: summary of the Guiding Principles for the governance of high-cost medicines in Australian hospitals - [link](#)

- Letter: Managing cancer-related pain in the setting of proven IgE-mediated opioid anaphylaxis - [link](#)

International Journal of Clinical Pharmacy

- Implementation and evaluation of specialist heart failure pharmacist prescribing clinics - [link](#)

- Exploring the impact of baseline platelet count on linezolid-induced thrombocytopenia: a retrospective single-center observation study - [link](#)

- Association of polypharmacy with clinical outcomes and healthcare utilization in older adults with cardiometabolic diseases: a retrospective cohort study - [link](#)

- Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion-positive non-small cell lung cancer in the United States - [link](#)

JAMA

- N-of-1 Studies in an Era of Precision Medicine - [link](#)

- Making Pragmatic Clinical Trials More Pragmatic - [link](#)

- Chronic Spontaneous Urticaria: A Review - [link](#)

- Dialysis for Chronic Kidney Failure: A Review - [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Decline of Mpox Antibody Responses After Modified Vaccinia Ankara–Bavarian Nordic Vaccination - [link](#)
- Patient Page: What Are Uterine Fibroids? - [link](#)
- COVID-19 Therapeutics for Nonhospitalized Older Adults - [link](#)

JAMA Cardiology

- Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial - [link](#)
- Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy: The CHAGASICS Randomized Clinical Trial - [link](#)
- Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure - [link](#)

JAMA Dermatology

- Global Antimicrobial Susceptibility Patterns of Staphylococcus aureus in Atopic Dermatitis: A Systematic Review and Meta-Analysis - [link](#)
- Efficacy and Safety of Crisugabalin (HSK16149) in Adults with Postherpetic Neuralgia: A Phase 3 Randomized Clinical Trial - [link](#)

JAMA Internal Medicine

- Clinician Specialty and HIV PrEP Prescription Reversals and Abandonments - [link](#)
- Masked Taper With Behavioral Intervention for Discontinuation of Benzodiazepine Receptor Agonists: A Randomized Clinical Trial - [link](#)

JAMA Network Open

- Semaglutide and Opioid Overdose Risk in Patients with Type 2 Diabetes and Opioid Use Disorder - [link](#)

JAMA Neurology

- Antiseizure Medications and Cardiovascular Events in Older People with Epilepsy - [link](#)
- Barriers to Tofersen Therapy for Variant SOD1-Mediated ALS - [link](#)

JAMA Oncology

- Prevalence and Factors Associated with Prostate Cancer Among Transgender Women - [link](#)

JAMA Pediatrics

- Cannabinoids Used for Medical Purposes in Children and Adolescents: A Systematic Review and Meta-Analysis - [link](#)

Journal of Allergy and Clinical Immunology

- Effects of pregnancy and lactation prebiotics supplementation on infant allergic disease: A randomized controlled trial - [link](#)
- Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP - [link](#)

Journal of the American College of Cardiology

- The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial - [link](#)
- Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy - [link](#)
- Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial - [link](#)

Journal of the American Geriatrics Society

- Association between potentially inappropriate medications prescription and health-related quality of life among US older adults - [link](#)

- Cardiovascular health, measured using Life's Essential 8, is associated with reduced dementia risk among older men and women - [link](#)

Journal of Clinical Endocrinology and Metabolism

- Habitual Coffee, Tea, and Caffeine Consumption, Circulating Metabolites, and the Risk of Cardiometabolic Multimorbidity - [link](#)

Journal of Clinical Oncology

- Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study - [link](#)

- Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2 - [link](#)

Journal of Patient Safety

- Implementation and Evaluation of Clinical Decision Support for Apixaban Dosing in a Community Teaching Hospital - [link](#)

Journal of Pharmacy Practice and Research (JPPR)

- Active Ingredient Prescribing in Australia: exploring pharmacists' experiences - [link](#)

- A retrospective study of duloxetine for phantom limb pain post lower-limb amputation - [link](#)

- Impact of sacubitril/valsartan on atrial fibrillation burden in heart failure: a retrospective observational study - [link](#)

Lancet

- Endovascular management of acute stroke - [link](#)

- Hypothyroidism - [link](#)

- WHO shapes priorities for medicines? An analysis of the applicants and decision makers within the historical evolution of the WHO Model Lists of Essential Medicines - [link](#)

Lancet HIV

- HIV incidence in people receiving government-subsidised pre-exposure prophylaxis in Australia: a whole-of-population retrospective cohort study - [link](#)

Lancet Infectious Diseases

- Advancing the chemotherapy of tuberculous meningitis: a consensus view - [link](#)

- New WHO guidelines for treating rhodesiense human African trypanosomiasis: expanded indications for fexinidazole and pentamidine - [link](#)

Lancet Oncology

- Challenges and opportunities for early phase clinical trials of novel drug–radiotherapy combinations: recommendations - [link](#)

- Rising costs of cancer medicines - [link](#) ; The tyranny of non-inferiority trials - [link](#)

Lancet Public Health

- Long-term waning of vaccine-induced immunity to measles in England: a mathematical modelling study - [link](#)

Lancet Respiratory Medicine

- Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial - [link](#)

- Respiratory Syncytial Virus 2024 - [link](#)

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Discrepancy between Subjective and Objective Measurements for the Evaluation of Medication Adherence—A Cross-Sectional Study in Patients with Cardiovascular Diseases - [link](#)
- Clinical Outcomes of Benzodiazepine Prescribing for People Receiving Opioid Agonist Treatment: A Systematic Review of the Evidence - [link](#)

Medical Journal of Australia

- Adherence to clinical care standards and mortality after hip fracture surgery in New South Wales, 2015–2018: a retrospective population-based study - [link](#)
- Aligning legislation with clinical practice: off-label prescribing under the microscope - [link](#)
- Concurrent use of hormonal long-acting reversible contraception by women of reproductive age dispensed teratogenic medications, Australia, 2013–2021: a retrospective cohort study - [link](#)

Neurology

- Anti-CD20 Therapies in Drug-Naive Patients with Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study - [link](#)
- Duration of Benefit and Risk of Dual Antiplatelet Therapy up to 72 Hours After Mild Ischemic Stroke and Transient Ischemic Attack - [link](#)

New England Journal of Medicine

- Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B - [link](#)
- Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection - [link](#)
- Neuroleptic Malignant Syndrome - [link](#)

Pediatr Qual Saf

- Reducing falls in hospitalized children and adolescents with cancer and blood disorders: a quality improvement journey - [link](#)

Pediatrics (American Academy of Pediatrics)

- Evidence for the Use of Opioid Medication for Pediatric Acute Pain in the Outpatient Setting: Technical Report - [link](#)
- Opioid Prescribing for Acute Pain Management in Children and Adolescents in Outpatient Settings: Clinical Practice Guideline - [link](#)

Pharmacotherapy

- Intravenous ketamine successfully treats treatment-resistant catatonia in schizophrenia: A case report - [link](#)
- Efficacy and safety of mirikizumab compared with currently approved biologic drugs for the treatment of ulcerative colitis: A systematic review and network meta-analysis - [link](#)

Prescribe International - [October 2024](#) includes

- Finerenone (Kerendia[®]) in chronic kidney disease with albuminuria associated with type 2 diabetes
- Solifenacin + tamsulosin (Vecalmys[®]/Vesomni[®]) in benign prostatic hyperplasia: not acceptable
- Short-term interruption of treatment with a xaban or dabigatran: [treatment interruption](#), even for one day, was associated with a 2-fold increase in the risk of premature death and a 10-fold increase in the risk of stroke, transient ischaemic attack or systemic embolism.
- Drugs to avoid in the name of better patient care - [2024 update](#)

Thorax

- Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD - [link](#)

CONSULTATIONS (new additions in bold)

Agency for Clinical Innovation, NSW (ACI)

- Consultation: Stroke Intravenous Thrombolysis - Closes 11 October 2024 - [link](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Draft Medication Management at Transitions of Care Stewardship Framework - Closing 27 October 2024 - [link](#)

TGA

- Public consultation on interim decisions to amend the Poisons Standard - ACMS, ACCS & Joint ACMS-ACCS JUNE, 2024 - Closes on 18 October 2024 - [link](#)

- Consultation: Proposed amendments to the Poisons Standard – ACMS and Joint ACMS-ACCS meetings, November 2024 - Closes on 22 October 2024 – [link](#)

WEBINARS & PODCASTS

Australian Prescriber Podcasts

- [Episode 173](#): Management of occupational exposure to blood and body fluids in primary care

FDA Division of Drug Information is presenting a [series](#) of CE webinars

- The Bad Ad Program - September 24, 2024 - [link](#)

MJA Podcasts

- [Episode 26](#): What have we learned about TAVI in low risk patients?

- [Episode 25](#): Gastric and oesophageal cancer - a community perspective

UPCOMING EVENTS

AHHA

- The John Deeble Lecture and Panel Discussion, Beyond boundaries: leadership for health - National Museum of Australia, Canberra, ACT - October 15, 2024 09:00-16:00 AEST – [register](#)

- Embedding patient-reported measures in practice – October 29, 2024, 12:30-13:00 AEDT - [register](#)

AHRQ

- Improving Hospital Handoffs Using AHRQ's Surveys on Patient Safety Culture® Hospital Survey – webinar - Oct. 30, 2024 13:00-14:00 ET - [register](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- First national Chronic Obstructive Pulmonary Disease Clinical Care Standard Launch, with expert panel discussion - Thursday 17 October 12:00–13:00 AEDT - [register](#)

- NMS 2024: Ageing well: safe medicines, better lives – Tuesday, 19 November 2024 10.00- 15.00 - [Register](#)

Canadian Pharmacists Association

- Practice Development: Tools pharmacists can use to help sow the seed of deprescribing – free webinar - Thursday, October 17 | 12:00-13:00 ET - [register](#)

Institute for Healthcare Improvement-BMJ Group

- The International Forum on Quality and Safety in Healthcare, Brisbane, 6-8 November 2024 – [registration](#)

Society of Hospital Pharmacists (SHPA)

- Medicines Management 2024 MM2024, Adelaide, 14-16 November 2024 - early-bird [registration](#) closes 11:59pm AEST Thursday 3 October 2024

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091